143 related articles for article (PubMed ID: 37191138)
1. Characteristics and outcome of severe hypercalcemia on admission to the emergency department: a retrospective cohort study.
Ravioli S; Lafranchi A; Exadaktylos AK; Haidinger M; Lindner G
Swiss Med Wkly; 2023 Apr; 153():40069. PubMed ID: 37191138
[TBL] [Abstract][Full Text] [Related]
2. Hypercalcemia in the ED: prevalence, etiology, and outcome.
Lindner G; Felber R; Schwarz C; Marti G; Leichtle AB; Fiedler GM; Zimmermann H; Arampatzis S; Exadaktylos AK
Am J Emerg Med; 2013 Apr; 31(4):657-60. PubMed ID: 23246111
[TBL] [Abstract][Full Text] [Related]
3. Severe hypocalcemia in the emergency department: a retrospective cohort study of prevalence, etiology, treatment and outcome.
Haidinger M; Putallaz E; Ravioli S; Exadaktylos A; Lindner G
Intern Emerg Med; 2024 Jun; ():. PubMed ID: 38839645
[TBL] [Abstract][Full Text] [Related]
4. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ
J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993
[TBL] [Abstract][Full Text] [Related]
5. Successful Hemodialysis Treatment of Severe Hypercalcemia Following COVID-19 in Multiple Myeloma: A Case Report.
Goss CH; Ezaldin S; Aijaz P; Anees A
Am J Case Rep; 2023 Aug; 24():e940835. PubMed ID: 37559361
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and risk factors for hypercalcemia among non-dialysis patients with chronic kidney disease-mineral and bone disorder.
Seng JJB; Tan YLC; Lim RW; Ng HTS; Lee PH; Wong J
Int Urol Nephrol; 2018 Oct; 50(10):1871-1877. PubMed ID: 29882003
[TBL] [Abstract][Full Text] [Related]
7. Hypercalcemia in the emergency department.
Lee CT; Yang CC; Lam KK; Kung CT; Tsai CJ; Chen HC
Am J Med Sci; 2006 Mar; 331(3):119-23. PubMed ID: 16538071
[TBL] [Abstract][Full Text] [Related]
8. Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myeloma.
Buege MJ; Do B; Lee HC; Weber DM; Horowitz SB; Feng L; Qing Y; Shank BR
Cancer Treat Res Commun; 2019; 21():100159. PubMed ID: 31521048
[TBL] [Abstract][Full Text] [Related]
9. Hypercalcemia in the nephrology department patients - incidence, etiology and impact on renal function.
Królewicz K; Steć Z; Niemczyk S
Pol Merkur Lekarski; 2021 Feb; 49(289):9-12. PubMed ID: 33713085
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy.
Khan AA; Gurnani PK; Peksa GD; Whittier WL; DeMott JM
Ann Pharmacother; 2021 Mar; 55(3):277-285. PubMed ID: 32885992
[TBL] [Abstract][Full Text] [Related]
11. Is severe hypercalcemia immediately life-threatening?
Guimard C; Batard E; Lavainne F; Trewick D
Eur J Emerg Med; 2018 Apr; 25(2):110-113. PubMed ID: 28338532
[TBL] [Abstract][Full Text] [Related]
12. Calcium levels on admission and before discharge are associated with mortality risk in hospitalized patients.
Akirov A; Gorshtein A; Shraga-Slutzky I; Shimon I
Endocrine; 2017 Aug; 57(2):344-351. PubMed ID: 28667379
[TBL] [Abstract][Full Text] [Related]
13. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
[TBL] [Abstract][Full Text] [Related]
14. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center.
Vassilopoulou-Sellin R; Newman BM; Taylor SH; Guinee VF
Cancer; 1993 Feb; 71(4):1309-12. PubMed ID: 8382106
[TBL] [Abstract][Full Text] [Related]
15. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
16. PTHrP-mediated hypercalcemia: causes and survival in 138 patients.
Donovan PJ; Achong N; Griffin K; Galligan J; Pretorius CJ; McLeod DS
J Clin Endocrinol Metab; 2015 May; 100(5):2024-9. PubMed ID: 25719931
[TBL] [Abstract][Full Text] [Related]
17. Overview of hypercalcemia of malignancy.
Solimando DA
Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S4-7. PubMed ID: 11757205
[TBL] [Abstract][Full Text] [Related]
18. [The etiology of hypercalcemia: a study of 47 cases in a hospital internal medicine service].
Azzabi S; Khalfallah N; Ben Hassine L; Omar S; Kooli C; Hamza M; Haddad A
Tunis Med; 2001; 79(6-7):348-52. PubMed ID: 11771429
[TBL] [Abstract][Full Text] [Related]
19. Hypercalcemia caused by humoral effects and bone damage indicate poor outcomes in newly diagnosed multiple myeloma patients.
Bao L; Wang Y; Lu M; Chu B; Shi L; Gao S; Fang L; Xiang Q
Cancer Med; 2020 Dec; 9(23):8962-8969. PubMed ID: 33145966
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study of serum calcium levels in a hospital population in Malaysia.
Aishah AB; Foo YN
Med J Malaysia; 1995 Sep; 50(3):246-9. PubMed ID: 8926903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
